Alvotech Files Routine 6-K Report
Ticker: ALVOW · Form: 6-K · Filed: Jul 2, 2024 · CIK: 1898416
| Field | Detail |
|---|---|
| Company | Alvotech (ALVOW) |
| Form Type | 6-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 6-K, biopharmaceutical
TL;DR
Alvotech filed a standard 6-K, no major news.
AI Summary
Alvotech, a biopharmaceutical company, filed a Form 6-K on July 2, 2024, reporting for the month of July 2024. The company, incorporated in Luxembourg, is primarily engaged in the development and manufacturing of biosimilar medicines. This filing is routine and does not contain specific financial figures or significant operational updates.
Why It Matters
This filing indicates Alvotech is meeting its regulatory reporting obligations as a foreign private issuer. Investors can monitor these filings for any material updates.
Risk Assessment
Risk Level: low — This is a routine filing with no new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Alvotech (company) — Registrant
- 001-41421 (company) — SEC File Number
- 20240702 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, have filed or are required to file with a stock exchange, or have distributed or are required to distribute to their security holders.
What is Alvotech's primary business?
Alvotech is a biopharmaceutical company focused on the development and manufacturing of biosimilar medicines.
Where is Alvotech headquartered?
Alvotech's principal executive office is located at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.
Does Alvotech file annual reports under Form 20-F?
Yes, Alvotech indicates it files annual reports under cover of Form 20-F.
What is the filing date of this specific Form 6-K?
This Form 6-K was filed on July 2, 2024.
Filing Stats: 348 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-07-02 06:38:32
Filing Documents
- f6k_070224.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 4KB
- 0001171843-24-003757.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alvotech (Registrant) Date: July 1, 2024 /s/ Tanya Zharov Tanya Zharov General Counsel